Analyst Conference Summaries

Biotechnology Investor Aids

Cidara Therapeutics
CDTX

conference date: August 3, 2023 press release only.

Cidara Therapeutics Could Soar on Rezafungin Approval [Seeking Alpha, November 11, 2022]

Cidara Therapeutics: Rezafungin Data Could Bring Value [Seeking Alpha, July 20, 2021]

2023
Cidara Therapeutics Q1 2023 Press Release Cidara Therapeutics Q2 2023 Press Release Cidara Therapeutics Q3 2023 Press Release  
May 11, 2023 Aug. 3, 2023 Nov. 2, 2023  
2022
Cidara Therapeutics Q1 2022 Press Release Cidara Therapeutics Q2 2022 Press Release Cidara Therapeutics Q3 2022 Press Release Cidara Therapeutics Q4 2022 Press Release
May 11, 2022 Aug. 9, 2022 Nov. 3, 2022 March 23, 2023
2021
Cidara Therapeutics Q1 2021 Press Release Cidara Therapeutics Q2 2021 Press Release Cidara Therapeutics Q3 2021 Press Release Cidara Therapeutics Q4 2021 Press Release
May 13, 2021 Aug. 12, 2021 Nov. 10, 2021 March 7, 2022

Cidara Therapeutics (CDTX) is a clinical-stage biotechnology company specializing in therapies for viral and fungal infections.

Cidara Therapeutics web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 FATE
 GILD
 GLYC
 ILMN
 INO
 IONS
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SANA
 SYRS
 VBLT
 VRTX
 VSTM
 WBA
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2023 William P. Meyers